St John's wort interferes with chemotherapy, study shows

doi:10.1136/bmj.325.7362.460/c

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ research articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Deborah Josefson Nebraska

Cancer patients who take the herbal remedy St John's wort (Hypericum perforatum) may jeopardise their response to chemotherapy, according to a small study that examined the effect of the herb on the metabolism of the antineoplastic agent irinotecan (Journal of the National Cancer Institute 2002;94:1247-9).

St John's Wort is known to induce the cytochrome P450 hepatic enzyme system. Specifically, the herb induces the expression of an isoform of the P450 enzyme system known as CYP3A4. This enzymatic cascade is heavily used by the body to break down a variety of drugs and toxins.

More than half of the chemotherapeutic agents now used are broken down …